Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC
Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.
Read More
Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC
Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.
Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer